Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06101966
Starting soon Observational

A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

NCT06101966 · tracked via the Priya Life Science China tracker
Sponsor
Fujian Cancer Hospital
Phase
Observational
Started
2023-12-01
Last updated
2023-10-26

Condition(s) studied

Cervical CancerRadiotherapyDistant MetastasisPrognostic ModelRisk Factor

Investigational drug(s) / intervention(s)

external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)

external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT): Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.

Study summary

This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * patients confirmed as cervical cancer by biopsies and treated with radiotherapy were initially enrolled Exclusion Criteria: * (1) patients treated with surgery. (2) patient received incomplete treatment somewhere else. (3) patients with cancer history. (4) patients with pelvic surgery history. (5) patients without complete pre-treatment medical information. (6) patients with unfinished radical radiotherapy. (7) patients suffered from metastasis within 3 months after radiotherapy. (8) patients without complete 1-year follow-up materials

Primary outcome measure(s)

  • Early distant metastases — 3-12months
    Early distant metastasis defines as metastasis occurrence between 3 -12 months after radiotherapy.

Trial sites (1)

FacilityCityRegionStatus
Fujian Cancer Hospital Fuzhou Fujian

More Fujian Cancer Hospital trials in China

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC Recruiting
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Recruiting
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors Active, not recruiting
Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma Starting soon
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Recruiting

Other trials for the same condition

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Recruiting
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer Recruiting
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer Starting soon
Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06101966 on ClinicalTrials.gov ↗ ← All trials in China